Literature DB >> 856437

High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis.

D M Hayes, E Cvitkovic, R B Golbey, E Scheiner, L Helson, I H Krakoff.   

Abstract

A clinical trial was undertaken to improve the therapeutic index of cis-platinum diammine dichloride with a concomitantly administered mannitol induced diuresis. Sixty patients, heavily pretreated, were entered; fifty-one are evaluable. The technique of concomitant osmotic diuresis and CPDD administration is described in detail. Doses ranged from 3 mg/kg to 5 mg/kg. At 5 mg/kg, dose-limiting renal, marrow and ototoxicity were seen, and resulted in one drug death. Marrow toxicity was moderate. Renal toxicity was limited to transient elevations in serum creatinine levels, except in some patients who had renal impairment prior to CPDD treatment. These patients had moderate renal toxicity. Serial treatments as frequently as once every 3 weeks were used to maintain responses. Serial high dose CPDD produced only mild renal dysfunction. Ototoxicity, usually subclinical, was quantitated audiometrically, and found to be dose related, but not clinically prohibitive at 4 mg/kg or less. The overall response rate (PR/MR) was 42%. Clinically significant responses in epidermoid carcinoma of the head and neck, adenocarcinoma of the ovary, and germ cell tumors of the testis were seen. All six responding patients with germ cell tumor of the testis, had been resistant to low dose (1mg/kg) CPDD. Two responding patients with ovarian adenocarcinoma had been resistant to alkylating agents.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 856437     DOI: 10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  109 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Mitomycin C, vinblastine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer.

Authors:  F Nomura; K Shimokata; H Saito; S Sakai; A Watanabe; H Saka
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Determination of cis-diamminedichloroplatinum (II) in plasma proteins and hemoglobin of cancer patients.

Authors:  R Mustonen; P Hietanen; S Leppälä; M Takala; K Hemminki
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

4.  Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats.

Authors:  N M Osman; M P Copley; C L Litterst
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 5.  A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.

Authors:  Daniel J Crona; Aimee Faso; Tomohiro F Nishijima; Kathleen A McGraw; Matthew D Galsky; Matthew I Milowsky
Journal:  Oncologist       Date:  2017-04-24

6.  Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide.

Authors:  H T Heidemann; J F Gerkens; E K Jackson; R A Branch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

7.  Cisplatin-induced ototoxicity: audiometric findings and experimental cochlear pathology.

Authors:  K Böheim; E Bichler
Journal:  Arch Otorhinolaryngol       Date:  1985

8.  Cisplatin-associated anemia: an erythropoietin deficiency syndrome.

Authors:  P A Wood; W J Hrushesky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

9.  Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.

Authors:  P K Buamah; A Howell; H Whitby; E S Harpur; A Gescher
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.

Authors:  R Parti; W Wolf
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.